Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Β-D-Mannuronic Acid (M2000) and Inflammatory Cytokines in Covid-19; an in Vitro Study Publisher Pubmed



Robatjazi B1 ; Ghorban K1, 2 ; Gholami M2, 3 ; Samizadeh E4 ; Aghazadeh Z5 ; Shahrbaf MA6 ; Dadmanesh M2, 7 ; Rouzbahani NH1, 2 ; Mirshafiey A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Immunology, School of Medicine, Aja University of Medical Sciences, Tehran, Iran
  2. 2. Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran
  3. 3. Department of Microbiology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pathology, Imam Reza Hospital, Aja University of Medical Sciences, Tehran, Iran
  5. 5. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Department of Infectious Diseases, School of Medicine, Aja University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Allergy# Asthma and Immunology Published:2022


Abstract

coronavirus disease of 2019 (COVID-19) can be complicated by acute respiratory distress syndrome (ARDS) and may be associated with cytokine storm and multiorgan failure. Anti-inflammatory agents, such as systemic corticosteroids, monoclonal antibodies, and nonsteroidal anti-inflammatory drugs (NSAIDs) can be used for this purpose. In this study, we evaluated the immunomodulatory effect of mannuronic acid (M2000), which is a novel NSAID, on COVID-19related cytokine storms. This study was conducted in vitro on blood samples of 30 COVID-19 patients who presented with ARDS to a referral center. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples and incubated with phorbol myristate acetate for 24 hours. M2000 was administered with the dosages of 25 µg/well and 50 µg/well after 4 hours of incubation at 37°C. The quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to assess mRNA gene expression. Enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the supernatant PBMC levels of interleukin (IL)-6, IL-17, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ. Both mRNA expression and the supernatant PBMC levels of IL-17, TNF-α, IL-6, and IFN-γ were decreased in PBMCs of COVID-19 patients treated with M2000 compared with the control group. For the first time, it was observed that M2000 could be effective in alleviating the inflammatory cascade of COVID-19 patients based on an in vitro model. After further studies in vitro and in animal models, M2000 could be considered a novel NSAID drug in COVID-19 patients. Copyright © 2022 Robat-Jazi et al.
Related Docs
View other Related Docs
1. Influence of Β-D-Mannuronic Acid, As a New Member of Non-Steroidal An-Ti-Inflammatory Drugs Family, on the Expression Pattern of Chemokines and Their Receptors in Rheumatoid Arthritis, Current Drug Discovery Technologies (2021)
2. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)
3. Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients, Iranian Journal of Allergy# Asthma and Immunology (2022)
4. International Multicenter Randomized, Placebo-Controlled Phase Iii Clinical Trial of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2019)
5. Dysregulated Mirnas Network in the Critical Covid-19: An Important Clue for Uncontrolled Immunothrombosis/Thromboinflammation, International Immunopharmacology (2022)
6. The Role of Β-D-Mannuronic Acid, As a New Non-Steroidal Anti-Inflammatory Drug on Expression of Mir-146A, Irak1, Traf6, Nf-Κb and Pro-Inflammatory Cytokines Following a Clinical Trial in Rheumatoid Arthritis Patients, Immunopharmacology and Immunotoxicology (2020)
7. Allogenic Mesenchymal Stromal Cells and Their Extracellular Vesicles in Covid-19 Induced Ards: A Randomized Controlled Trial, Stem Cell Research and Therapy (2023)
8. A Randomized, Controlled, Phase Ii Clinical Trial of Β-D-Mannuronic Acid (M2000) in Pre-Surgical Breast Cancer Patients at Early Stage (T1-T2), Clinical and Experimental Pharmacology and Physiology (2019)
Experts (# of related papers)
View all Related Experts
Mostafa Hosseini (9)
Ahmad Reza Jamshidi (8)
Other Related Docs
9. Efficacy of Β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules Nfҡb, Il-8 and Cd49d Using Healthy Donor Pbmc, Current Drug Discovery Technologies (2020)
10. Oral Administration Effects of Β-D-Mannuronic Acid (M2000) on Th17 and Regulatory T Cells in Patients With Ankylosing Spondylitis, Biomedicine and Pharmacotherapy (2018)
11. Immunopharmacological Effect of Β-D-Mannuronic Acid (M2000), As a New Immunosuppressive Drug, on Gene Expression of Mir-155 and Its Target Molecules (Socs1, Ship1) in a Clinical Trial on Rheumatoid Arthritis Patients, Drug Development Research (2020)
12. Anti-Diabetic Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property on Insulin Production, Blood Glucose, and Inflammatory Markers in the Experimental Diabetes Model, Archives of Physiology and Biochemistry (2019)
13. An in Vitro Assessment for Evaluating the Efficiency of Β-D-Mannuronic Acid (M2000) in Myelodysplastic Syndrome, Journal of Cellular Physiology (2019)
14. The Inhibitory Role of M2000 (Β-D-Mannuronic Acid) on Expression of Toll-Like Receptor 2 and 4 in Ht29 Cell Line, Recent Patents on Inflammation and Allergy Drug Discovery (2019)
15. A Controlled, Randomized Phase Ii Clinical Trial for Efficacy and Safety Evaluation of Mannuronic Acid in Secondary Progressive Form of Multiple Sclerosis, International Journal of Neuroscience (2022)
16. The Effects of Mannuronic Acid on Il-1Β, Il-17A, Stat1, and Stat3 Gene Expressions and Tlr2 and Tlr4 Molecules in Multiple Sclerosis, Journal of Clinical Pharmacology (2022)
17. Clinical Improvement of Diabetes Mellitus Type 1 by Β-D-Mannuronic Acid (M2000) in a Breast Cancer Patient - As a Case Report, Clinical Diabetology (2019)
18. Evaluation of Cell Adhesion Molecules (Lfa-1 and L-Selectin) in Ankylosing Spondylitis Patients After Treatment With ß-D-Mannuronic Acid (M2000), Indian Journal of Medical Research (2023)
19. Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes, Journal of Clinical Pharmacology (2020)
20. Introduction of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property Based on Cox-1/Cox-2 Activity and Gene Expression, Pharmacological Reports (2017)
21. The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients, Current Drug Discovery Technologies (2020)
22. The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients, Recent Patents on Inflammation and Allergy Drug Discovery (2020)
23. The Anti-Tumoral Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Treg Cells Frequency and Mmp-2, Mmp-9, Ccl22 and Tgfβ1 Gene Expression in Pre-Surgical Breast Cancer Patients, Iranian Journal of Allergy# Asthma and Immunology (2019)
24. Covid-19 Pathology on Various Organs and Regenerative Medicine and Stem Cell-Based Interventions, Frontiers in Cell and Developmental Biology (2021)
25. Effect of Β-D-Mannuronic Acid (M2000) on Oxidative Stress Enzymes’ Gene Using Healthy Donor Peripheral Blood Mononuclear Cells for Evaluating the Anti-Aging Property, Current Drug Discovery Technologies (2019)
26. A Phase I/Ii Randomized, Controlled, Clinical Trial for Assessment of the Efficacy and Safety of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2018)
27. Evaluation of the Effect of Mannuronic Acid As a Novel Nsaid With Immunosuppressive Properties on Expression of Socs1, Socs3, Ship1, and Traf6 Genes and Serum Levels of Il-6 and Tnf-Α in Patients With Multiple Sclerosis, Journal of Clinical Pharmacology (2021)
28. Assessment of Biochemical Determinants in Multiple Sclerosis Patients Following the Oral Administration of Β-D-Mannuronic Acid (M2000), Current Drug Discovery Technologies (2021)
29. Anti-Tumor Effect of M2000 (Β-D-Mannuronic Acid) on the Expression of Inflammatory Molecules in the Prostate Cancer Cell, Immunopharmacology and Immunotoxicology (2021)
30. Effects of Mannuronic Acid (M2000) on Gene Expression Profile of Signal Transducer and Activator of Transcription Proteins (Stats) in Rheumatoid Arthritis Patients, Reumatismo (2020)
31. Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (Β-D-Mannuronic Acid) As a Novel Nsaid With Immunosuppressive Property, Endocrine# Metabolic and Immune Disorders - Drug Targets (2018)
32. Anti-Angiogenesis Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Properties Under Experimental Model, Clinical and Experimental Pharmacology and Physiology (2018)
33. Evaluation of the Efficacy and Safety of Β-D-Mannuronic Acid in Patients With Ankylosing Spondylitis: A 12-Week Randomized, Placebo-Controlled, Phase I/Ii Clinical Trial, International Immunopharmacology (2018)
34. Immunotherapeutic Effects of Β-D Mannuronic Acid on Il-4, Gata3, Il-17 and Rorc Gene Expression in the Pbmc of Patients With Inflammatory Bowel Diseases, Iranian Journal of Allergy# Asthma and Immunology (2018)
35. The Anti-Migraine Effects of M2000 (Β-D-Mannuronic Acid) on a Patient With Rheumatoid Arthritis: Case Report, Current Clinical Pharmacology (2017)
36. Multisystem Inflammatory Syndrome and Autoimmune Diseases Following Covid-19: Molecular Mechanisms and Therapeutic Opportunities, Frontiers in Molecular Biosciences (2022)
37. Cardioprotective Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Gene Expression of Oxldl Scavenger Receptors in the Experimental Diabetic Model, Immunopharmacology and Immunotoxicology (2018)
38. Immunomodulatory Effects of M2000 (Β-D-Mannuronic Acid) on Tnf-Α, Il-17 and Foxp3 Gene Expression in Patients With Inflammatory Bowel Disease, International Immunopharmacology (2017)
39. The Effect of Β-D-Mannuronic Acid in Animal Model of Epilepsy, Natural Product Communications (2020)
40. Targeting of Circulating Th17 Cells by Β-D-Mannuronic Acid (M2000) As a Novel Medication in Patients With Rheumatoid Arthritis, Inflammopharmacology (2018)
41. Pharmacological Effects of Β-D-Mannuronic Acid (M2000) on Mir-146A, Irak1, Traf6 and Nf-Κb Gene Expression, As Target Molecules in Inflammatory Reactions, Pharmacological Reports (2017)
42. Critical Roles of Cytokine Storm and Bacterial Infection in Patients With Covid-19: Therapeutic Potential of Mesenchymal Stem Cells, Inflammopharmacology (2023)
43. Complement System As the Potential Therapeutic Target in the Management of Covid-19 Patients, Trends in Immunotherapy (2022)
44. Immunomodulatory Effect of G2013 (Α-L-Guluronic Acid) on the Tlr2 and Tlr4 in Human Mononuclear Cells, Current Drug Discovery Technologies (2018)
45. The Evaluation of Hematological Parameters and Their Correlation With Disease Prognosis in Covid-19 Disease in Iran, International Journal of Hematology-Oncology and Stem Cell Research (2023)
46. Diabetes As One of the Long-Term Covid-19 Complications: From the Potential Reason of More Diabetic Patients’ Susceptibility to Covid-19 to the Possible Caution of Future Global Diabetes Tsunami, Inflammopharmacology (2023)
47. Modulation of Macrophage Polarization for Bone Tissue Engineering Applications, Iranian Journal of Allergy# Asthma and Immunology (2018)
48. The Potent Suppressive Effect of Β-D-Mannuronic Acid (M2000) on Molecular Expression of the Tlr/Nf-Kb Signaling Pathway in Ankylosing Spondylitis Patients, International Immunopharmacology (2017)
49. Formation and Activity of Nlrp3 Inflammasome and Histopathological Changes in the Lung of Corpses With Covid-19, Journal of Molecular Histology (2022)
50. Beyond Prediction: Unveiling the Prognostic Power of Μ-Opioid and Cannabinoid Receptors, Alongside Immune Mediators, in Assessing the Severity of Sars-Cov-2 Infection, BMC Infectious Diseases (2024)